首页> 美国卫生研究院文献>other >The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity
【2h】

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity

机译:相对剂量强度在胰腺导管腺癌辅助化疗中的意义-包括影响相对剂量强度的临床病理因素分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recently, it has been reported that the relative dose intensity (RDI) of adjuvant chemotherapy (AC) influences survival in various cancers, but there are very few reports about RDI in pancreatic ductal adenocarcinoma (PDAC). The optimal timing for initiation of AC for PDAC also remains unknown. The aim of this study was to identify the significance of RDI and the time interval between surgery and initiation of AC on survival of patients with PDAC. Clinicopathological factors that affect RDI were also investigated.A total of 311 consecutive PDAC patients who underwent curative resection between May 2005 and January 2015 were enrolled. Patients who underwent neoadjuvant chemoradiation, had UICC stage IV disease, or had early recurrences within 6 months were excluded, and the remaining 168 cases were analyzed.Patients with RDIs ≥80% (n = 79) showed significantly better overall survival (OS) compared to patients with RDIs <80% (n = 55) (median survival time (MST): 45.6 months, 26.0 months, P < 0.001). Patients with no AC (n = 34) showed the worst OS (MST: 20.8 months). Whether the AC was initiated earlier or later than 8 weeks after surgery did not influence survival, either in patients with RDIs ≥80% (P = 0.79) or in those with <80% (P = 0.73). Patients in the S-1 monotherapy group (n = 49) showed significantly better OS than patients in the gemcitabine monotherapy group (n = 51) (MST: 95.0 months, 26.0 months, respectively; P = 0.001). Univariate analysis conducted after adjusting for the chemotherapeutic drug used identified several prognostic factors; male gender (P = 0.01), intraoperative blood transfusion (P = 0.005), lymph node metastasis (P = 0.03), and postoperative WBC count (P = 0.03). Multivariate analysis identified intra-plus postoperative blood transfusion (P = 0.002) and high postoperative platelet-to-lymphocyte ratios (PLR) (P = 0.04) as independent predictors of poor RDI.Efforts to maintain RDI had a greater impact on survival than the struggle to start AC early after surgery. Intra-plus postoperative blood transfusion and a high postoperative PLR could be predictive markers of reduced RDI in AC of PDAC patients. Avoidance of perioperative blood transfusions where possible and nutritional support during the perioperative period could maintain adequate RDI and may lead to improved long-term outcome.
机译:最近,有报道称辅助化疗(AC)的相对剂量强度(RDI)影响各种癌症的存活率,但关于RDI在胰腺导管腺癌(PDAC)中的报道很少。 PDAC启动AC的最佳时序也仍然未知。这项研究的目的是确定RDI的意义以及从手术到开始AC之间的时间间隔对PDAC患者的生存。还研究了影响RDI的临床病理因素.2005年5月至2015年1月期间,共有311例接受根治性切除术的PDAC患者入组。排除接受新辅助化学放疗,UICC IV期疾病或在6个月内早期复发的患者,并对其余168例患者进行分析.RDI≥80%(n = 79)的患者的总生存率(OS)显着高于RDIs <80%(n = 55)(中位生存时间(MST):45.6个月,26.0个月,P months <0.001)。没有AC的患者(n = 34)表现出最差的OS(MST:20.8个月)。无论是在RDI≥80%(P = 0.79)或<80%(P = 0.73)的患者中,在手术后8周之前或之后开始AC都不会影响生存。与吉西他滨单药治疗组(n = 51)相比,S-1单药治疗组(n = 49)患者的OS显着改善(MST:分别为95.0个月,26.0个月; P = 0.001)。调整所用化疗药物后进行的单因素分析确定了几个预后因素。男性(P = 0.01),术中输血(P = 0.005),淋巴结转移(P = 0.03)和术后白细胞计数(P = 0.03)。多因素分析表明,术中加术后输血(P = 0.002)和术后血小板与淋巴细胞之比(PLR)高(P = 0.04)是RDI不良的独立预测因素。维持RDI的努力对生存的影响比对RDI的影响更大。努力在手术后早期开始AC。术中加术后输血和术后高PLR可能是PDAC患者AC中RDI降低的预测指标。尽可能避免围手术期输血和围手术期的营养支持可以维持足够的RDI,并可能改善长期预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号